Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Date

Click to order products descending

Display 45 Products per page

Disease Analysis: Triple-Negative Breast Cancer
Read More
Triple-negative breast cancer (TNBC) is a relatively rare breast cancer subtype. It is characterized by the absence of estrogen and progesterone receptors and does not involve the overexpression of HER2. TNBC is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. It accounts for roughly 14% of breast cancers.
May 20, 2022
Find out more
Disease Analysis: HR+/HER2- Breast Cancer
Read More
Hormone receptor-positive (HR+) is the most common breast cancer subtype, with approximately 70% of breast cancers presenting with overexpression of estrogen receptors, progesterone receptors, or both (De Placido and Pronzato, 2015). Overexpression of the hormone receptors allows estrogen and progesterone to drive tumor growth and proliferation. Therefore, endocrine therapy remains the standard treatment for advanced patients with HR+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
May 20, 2022
Find out more
Disease Analysis: HER2+ Breast Cancer
Read More
Amplification of the HER2/neu oncogene and related genetic elements on chromosome 17 increases HER2 expression and accelerates tumorigenesis. The natural disease progression meant that, historically, women with breast cancer who overexpressed HER2 were found to have significantly shorter disease-free survival and overall survival compared with women without HER2 amplification; however, the introduction of trastuzumab in 1998 drastically changed patient outcomes, to the point where HER2+ breast cancer patients now have the longest median survival of all breast cancer subtypes. HER2 is overexpressed in approximately 20% of breast cancers.
May 20, 2022
Find out more
Disease Analysis: Hepatocellular Carcinoma (HCC)
Read More
Liver cancers can be differentiated based on the cell types they affect. The most common form of liver cancer is hepatocellular carcinoma (HCC), which accounts for 80–90% of liver cancer cases. HCC affects hepatocellular cells, or hepatocytes, which are the most abundant cell type in the liver and are responsible for the liver’s primary functions, such as bile production, protein synthesis, and detoxification. This differentiates HCC from other types of liver cancer such as cholangiocarcinoma, which affects the epithelial cells lining the bile ducts, and angiosarcoma, which affects the endothelial cells lining blood vessels of the liver.
May 19, 2022
Find out more
Disease Analysis: Ovarian Cancer
Read More
Ovarian cancer is defined as a group of tumors that originate in the ovaries. Most ovarian cancers are epithelial carcinomas which begin in the tissue surrounding the ovary. Other less common types of ovarian tumors include primary peritoneal, fallopian tube, and malignant germ cell tumors. Ovarian cancer is the fourth most common cancer among women, and is the leading cause of gynecological cancer-related death in women.
May 19, 2022
Find out more
Disease Analysis: Gastric Cancer
Read More
Stomach or gastric cancer (GC) refers to any cancer arising in the lining of the stomach. The vast majority (95%) of these cancers are adenocarcinomas, and can be further grouped by anatomic origin. The clearest etiological distinction exists between adenocarcinomas of the gastric cardia (the anterior edge of the stomach surrounding the entry point of the esophagus), and those arising in the other anatomical subsites of the stomach – the fundus, body, pylorus, and the antrum. In most cases, gastric adenocarcinomas will begin in the muscularis mucosae and submucosa, then invading deeper lamina of the gastric wall.
May 18, 2022
Find out more
Disease Analysis: COVID-19 Prevention
Read More
COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of October 2021, there have been 245,373,039 confirmed cases of COVID-19, and 4,979,421 deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus.
May 17, 2022
Find out more
Disease Analysis: Dyslipidemia
Read More
Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated low-density lipoprotein cholesterol (LDL-C) due to the well-established link between excessively elevated LDL-C and atherosclerosis. As such, LDL-C is a major modifiable risk factor for cardiovascular (CV) disease, one of the world’s leading causes of morbidity and mortality, though differences in LDL particle morphology can also play a role. Other lipid level deviations in dyslipidemia include elevated triglycerides, low levels of high-density lipoprotein cholesterol (HDL-C), elevated total cholesterol, and elevated non-HDL-C, a marker of cholesterol in all atherogenic lipoproteins
May 13, 2022
Find out more
Disease Analysis: Epilepsy
Read More
Epilepsy is characterized by recurrent, unprovoked seizures, and is one of the most common chronic neurological disorders globally. A seizure is a transient manifestation of signs and/or symptoms, including a disturbance of consciousness, emotion, behavior, or motor function, which occurs because of abnormal excessive or synchronous neuronal activity in the brain.
May 6, 2022
Find out more
Disease Analysis: Human Papillomavirus (HPV) Vaccines
Read More
HPV is a member of the papillomavirus family, which are known for causing warts. Over 200 different types have been identified so far, and while most HPV infections are not harmful, persistent infection with certain HPV strains can cause warts and anogenital lesions, which if untreated may become cancers. HPV infection is the major cause of cervical cancers, with almost all cases (99%) being caused by HPV infection. Other cancers related to HPV include cancers of the vulva, vagina, penis, or anus. Only about 14 HPV strains are considered high risk for causing cervical cancer, and of these the two most common types, HPV 16 and 18, are responsible for causing around 70% of all cervical cancers globally.
May 5, 2022
Find out more
Market Spotlight: Chemotherapy-Induced Anemia

$1,318.00

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 5, 2022
Find out more
Disease Analysis: Seasonal Influenza Vaccines
Read More
Seasonal influenza is an acute viral infection that is spread by person-to-person transmission. Influenza, commonly referred to as the flu, circulates worldwide and can affect anyone in any age group, although annual epidemics peak during winter in temperate climates.
April 29, 2022
Find out more
Disease Analysis Atopic Dermatitis
Read More
Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. The condition usually begins during early infancy and childhood, but can persist into, or start during, adulthood.
April 22, 2022
Find out more
Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – US

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy and CD20-directed bispecific antibodies.
April 21, 2022
Find out more
Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy, and CD20-directed bispecific antibodies.
April 21, 2022
Find out more
Market Spotlight: Sarcoma

$1,318.00

This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 21, 2022
Find out more
Market Spotlight: Neuroendocrine tumors (NET)

$1,318.00

This Market Spotlight report covers the Neuroendocrine Tumors (NETs) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, upcoming and regulatory events, a 10-year disease incidence and prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
April 21, 2022
Find out more
Market Spotlight: Benign Prostatic Hyperplasia (BPH)

$1,318.00

This Market Spotlight report covers the Benign Prostatic Hyperplasia (BPH) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
April 21, 2022
Find out more
Disease Analysis: Diffuse Large B-Cell Lymphoma (DLBCL)
Read More
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin’s lymphoma (NHL), which originates in the lymphatic system when B lymphocytes become enlarged and proliferate uncontrollably to form a tumor mass. DLBCL can arise de novo or as a progression or transformation from more indolent disease such as chronic lymphocytic leukemia (in which case it is also known as Richter’s transformation) or follicular lymphoma (FL).
April 21, 2022
Find out more
Market Spotlight: Glioblastoma (GBM)

$1,318.00

This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 14, 2022
Find out more
Market Spotlight: Amyloidosis

$1,318.00

This Market Spotlight report covers the Amyloidosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
April 14, 2022
Find out more
Market Spotlight: Zika virus

$1,318.00

This Market Spotlight report covers the Zika Virus market, comprising key pipeline therapies, clinical trials, probability of success, and epidemiology.
April 14, 2022
Find out more
Market Spotlight: Esophageal Cancer

$1,318.00

This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 14, 2022
Find out more
Market Spotlight: Dry Eye Disease

$1,318.00

This Market Spotlight report covers the Dry Eye Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 14, 2022
Find out more
Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)

$1,318.00

This Market Spotlight report covers the Peripheral T-Cell Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 14, 2022
Find out more
Market Spotlight: Acute Lymphoblastic Leukemia (ALL)

$1,318.00

This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 13, 2022
Find out more
Disease Analysis: Dengue Vaccines
Read More
Dengue virus is a member of the Flaviviridae family, which are also known for causing other diseases including yellow fever, West Nile virus, and tick-borne encephalitis. There are four serologically distinct dengue viruses (DENV-1, DENV-2, DENV-3, and DENV-4), meaning that recovery from infection provides immunity against a specific serotype, but there is little to no cross-immunity towards other serotypes. As a result, a person can be infected multiple times in their lifetime, with subsequent infections being more likely to be severe due to a phenomenon called antibody-dependent enhancement of disease.
April 12, 2022
Find out more
Disease Analysis: Acute Myeloid Leukemia (AML)
Read More
AML is a type of heterogeneous hematological malignancy that originates from immature white blood cells (blasts) in the bone marrow, which may be derived from either a hematopoietic stem cell or a lineage-specific progenitor cell. “Acute” means that the leukemia may progress rapidly – AML generally spreads quickly to the bloodstream and can then spread to other parts of the body including the lymph nodes, spleen, central nervous system, and testicles.
April 11, 2022
Find out more
Disease Analysis: Bladder Cancer
Read More
Bladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally. Symptoms include hematuria, dysuria, increased urinary frequency, and frequent urinary tract infections.
April 8, 2022
Find out more
Disease Analysis: Depression
Read More
While it is not uncommon to experience feelings of sadness occasionally, in most people these emotions are usually fleeting and pass after a few days. When this manifests in a depressive disorder, a patient’s symptoms interfere with daily life and normal functioning. Depression is the leading cause of disability globally and can cause a multitude of symptoms, many of which are associated with impairment and, ultimately, decreased productivity
April 8, 2022
Find out more
Market Spotlight: Thyroid Cancer

$1,318.00

This Market Spotlight report covers the Thyroid Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, a 10-year disease incidence and five-year prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Market Spotlight: Irritable Bowel Syndrome (IBS)

$1,318.00

This Market Spotlight report covers the Irritable Bowel Syndrome (IBS) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Market Spotlight: Acne

$1,318.00

This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Market Spotlight: Hereditary Angioedema

$1,318.00

This Market Spotlight report covers the Hereditary Angioedema market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Market Spotlight: Celiac Disease

$1,318.00

Datamonitor Healthcare estimates that in 2019, there were approximately 121.1 million seropositive prevalent cases of celiac disease and 48.0 million prevalent cases of biopsy-proven celiac disease worldwide.
April 7, 2022
Find out more
Market Spotlight: Mantle Cell Lymphoma

$1,318.00

This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Disease Analysis: Cystic Fibrosis
Read More
Cystic fibrosis, caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) protein, is a rare and life-limiting genetic disorder that is characterized by thick, sticky mucus and pulmonary complications.
April 7, 2022
Find out more
Market Spotlight: Polycystic Ovary Syndrome (PCOS)

$1,318.00

This Market Spotlight report covers the Polycystic Ovary Syndrome (PCOS) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
April 7, 2022
Find out more
Market Spotlight: Atrial Fibrillation

$1,318.00

This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)
Read More
Lung cancer is generally categorized as either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). Of these, NSCLC is the most common type of lung cancer, accounting for roughly 85% of all cases. NSCLC can be further divided into non-squamous and squamous NSCLC histologies. Squamous NSCLC refers to patients with squamous cell carcinoma, whereas non-squamous NSCLC includes patients with adenocarcinoma, large cell carcinoma, and other less common subtypes. Incidence of adenocarcinoma and squamous cell carcinoma varies greatly by both geographic region and gender. In general, adenocarcinoma comprises approximately 30–50% of all lung cancer cases, while squamous cell carcinoma accounts for roughly 25–35%.
April 5, 2022
Find out more
Market Spotlight: Sjögren’s Syndrome

$1,318.00

This Market Spotlight report covers the Sjögren’s syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.
April 1, 2022
Find out more
Disease Analysis: Psoriatic Arthritis
Read More
Psoriatic arthritis is grouped with spondyloarthritis and is characterized by inflammation in the spine (spondylitis) and/or joints (arthritis). It is often preceded by a diagnosis of psoriasis by about 10 years. The disease may be characterized by joint pain, swelling, or morning stiffness, and about 80–90% of psoriatic arthritis patients experience nail lesions, which include pitting (dents) and onycholysis (detachment). Around 30% of individuals with psoriasis develop psoriatic arthritis.
March 30, 2022
Find out more
Disease Analysis: Schizophrenia
Read More
The current dynamics of the antipsychotic market show domination by atypical antipsychotics, mainly oral agents, but there is also increasing uptake of long-acting injectable (LAI) neuroleptics, which will continue. Oral atypical antipsychotics that were historical blockbusters are now facing intense generic erosion. The highest-selling oral antipsychotic is Latuda, one of the newer atypical drugs, but its market exclusivity is only set to last until 2023.
March 30, 2022
Find out more
Disease Analysis: Renal Cell Carcinoma (RCC)
Read More
Sutent is set to lose ground due to both newer, more effective treatments and imminent biosimilar erosion. Previously the SOC across many treatment settings, the pivotal trials of several newer therapies, which include checkpoint inhibitors Keytruda, Opdivo, and Bavencio, and the RTK inhibitor Cabometyx, have demonstrated significant clinical benefit over Sutent in the first-line setting. Keytruda and Cabometyx have also demonstrated benefit over Sutent in subsequent-line settings.
March 28, 2022
Find out more
Market Spotlight: Hidradenitis Suppurativa

$1,318.00

All of the approved drugs for hidradenitis suppurativa (HS) target tumor necrosis factor-alpha. These therapies are administered via the subcutaneous route, while Humira and Yuflyma are also available in intravenous formulations.
March 25, 2022
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *